Alexander Winter
YOU?
Author Swipe
View article: Bimodal inguinal sentinel lymph node imaging using a radiation-free fluorescent magnetic hybrid tracer in penile cancer patients
Bimodal inguinal sentinel lymph node imaging using a radiation-free fluorescent magnetic hybrid tracer in penile cancer patients Open
Invasive lymph node (LN) staging is crucial for survival in penile cancer (PeCa) patients. To lower patient morbidity associated with radical inguinal lymphadenectomy, sentinel node biopsy (SNB) is recommended. Application of conventional …
View article: The Significance of Biliary Anatomical Variation as a Key Indicator in Laparoscopic Bile Duct Injuries
The Significance of Biliary Anatomical Variation as a Key Indicator in Laparoscopic Bile Duct Injuries Open
Introduction: The science of Gastrointestinal (GI) endoscopy is the science and art of millimeters that has marvelously evolved over the past 30 years. Cholecystectomy, most of which is done laparoscopically, is one of the most common proc…
View article: Optimal Decision Mechanisms for Committees: Acquitting the Guilty
Optimal Decision Mechanisms for Committees: Acquitting the Guilty Open
A group of privately informed agents chooses between two alternatives. How should the decision rule be designed if agents are known to be biased in favor of one of the options? We address this question by considering the Condorcet Jury Set…
View article: Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours
Serum Levels of MicroRNA-371a-3p for Predicting the Histology of Postchemotherapy Residual Masses of Germ Cell Tumours Open
The microRNA-371a-3p (M371) test can identify about two-thirds of patients with viable cancer in residual metastatic masses following chemotherapy for germ cell tumours. Only masses with high percentages of viable cancer cells can be ident…
View article: Supplementary Table S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Table S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Table S1. Follow-up schedule of clinical stage I seminoma patients used in the study (modified from Oldenburg et al., Ann. Oncol. 2022, and Kliesch et al. Urol. int. 2021)
View article: Supplementary Table S2 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Table S2 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Table S2. Follow-up schedule of clinical stage I nonseminoma patients used in the study (modified from Oldenburg et al., Ann. Oncol. 2022, and Kliesch et al. Urol. int. 2021)
View article: Supplementary Figure S2 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Figure S2 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Figure S2. Frequencies of marker elevations in relapsing and non-relapsing patients
View article: Supplementary Figure S2 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Figure S2 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Figure S2. Frequencies of marker elevations in relapsing and non-relapsing patients
View article: Data from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Data from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Purpose:Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 tes…
View article: Supplementary Table S2 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Table S2 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Table S2. Follow-up schedule of clinical stage I nonseminoma patients used in the study (modified from Oldenburg et al., Ann. Oncol. 2022, and Kliesch et al. Urol. int. 2021)
View article: Supplementary Figure S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Figure S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Figure S1. Performance characteristics of M371 test for relapse detection, separate analysis of seminoma and nonseminoma
View article: Supplementary Table S3 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Table S3 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Table S3. Clinical details and relative expression values of 261 CS1 follow-up patients
View article: Supplementary Table S3 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Table S3 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Table S3. Clinical details and relative expression values of 261 CS1 follow-up patients
View article: Supplementary Table S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Table S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Table S1. Follow-up schedule of clinical stage I seminoma patients used in the study (modified from Oldenburg et al., Ann. Oncol. 2022, and Kliesch et al. Urol. int. 2021)
View article: Data from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Data from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Purpose:Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 tes…
View article: Supplementary Figure S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Figure S1 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Figure S1. Performance characteristics of M371 test for relapse detection, separate analysis of seminoma and nonseminoma
View article: Supplementary Table S4 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Table S4 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Table S4. Time of recurrences detection (months) with standard diagnostics and with M371 test
View article: Supplementary Table S4 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Supplementary Table S4 from Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Supplementary Table S4. Time of recurrences detection (months) with standard diagnostics and with M371 test
View article: Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study
Detection of Recurrence through microRNA-371a-3p Serum Levels in a Follow-up of Stage I Testicular Germ Cell Tumors in the DRKS-00019223 Study Open
Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 te…
View article: A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients
A Fluorescent and Magnetic Hybrid Tracer for Improved Sentinel Lymphadenectomy in Prostate Cancer Patients Open
In prostate cancer, sentinel lymph node dissection (sLND) offers a personalized procedure with staging ability which is at least equivalent to extended LND while inducing lower morbidity. A bimodal fluorescent–radioactive approach was intr…
View article: Changes in femoral rollback and rotation with increasing coupling in knee arthroplasty—a biomechanical in-vitro study
Changes in femoral rollback and rotation with increasing coupling in knee arthroplasty—a biomechanical in-vitro study Open
Background After total knee arthroplasty, 10–30% of patients still complain about knee pain, even after exact positioning of the components. Altered knee kinematics are crucial in this regard. The aim of our study was to experimentally det…
View article: Radioisotope-Guided Sentinel Lymph Node Biopsy in Penile Cancer: A Long-Term Follow-Up Study
Radioisotope-Guided Sentinel Lymph Node Biopsy in Penile Cancer: A Long-Term Follow-Up Study Open
Lymph node (LN) management is critical for survival in patients with penile cancer. However, radical inguinal lymphadenectomy carries a high risk of postoperative complications such as lymphedema, lymphocele, wound infection, and skin necr…
View article: Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer
Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer Open
ClinicalTrials.gov Identifier: NCT02111577.
View article: Magnetometer-Guided Sentinel Lymph Node Dissection in Prostate Cancer: Rate of Lymph Node Involvement Compared with Radioisotope Marking
Magnetometer-Guided Sentinel Lymph Node Dissection in Prostate Cancer: Rate of Lymph Node Involvement Compared with Radioisotope Marking Open
Sentinel pelvic lymph node dissection (sPLND) enables the targeted removal of lymph nodes (LNs) bearing the highest metastasis risk. In prostate cancer (PCa), sPLND alone or combined with extended PLND (ePLND) reveals more LN metastases al…
View article: Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial
Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial Open
Background: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial. Methods: In…